Cite
MLA Citation
Robert Z. Orlowski et al.. “A phase 2, randomized, double‐blind, placebo‐controlled study of siltuximab (anti‐IL‐6 mAb) and bortezomib versus bortezomib alone in patients with relapsed or refractory multiple myeloma.” American journal of hematology, vol. 90, no. 1, n.d., pp. 42–49. http://access.bl.uk/ark:/81055/vdc_100025006557.0x000004